Search results
Showing 766 to 780 of 2580 results for methods
Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517]
In development Reference number: GID-TA11669 Expected publication date: 03 September 2026
In development Reference number: GID-TA11566 Expected publication date: TBC
Plozasiran for treating familial chylomicronaemia syndrome [ID6593]
In development Reference number: GID-TA11793 Expected publication date: 18 November 2026
This quality standard covers the clinical assessment and management of depression in adults aged 18 and over. It describes high-quality care in priority areas for improvement.
View quality statements for QS8Show all sections
Sections for QS8
- Quality statements
- Quality statement 1: Assessment
- Quality statement 2: Discussing treatment options
- Quality statement 3: Preventing relapse
- Quality statement 4: Stopping antidepressants
- Quality statement 5: Access to services for adults from minority ethnic backgrounds
- Update information
- About this quality standard
Learn about NICE's proportionate approach to technology appraisals, which aims to streamline the evaluation process for new health technologies, ensuring timely access to innovative treatments while maintaining rigorous standards.
OCD Obsessive-compulsive disorder and body dysmorphic disorder
In development Reference number: GID-QS10200 Expected publication date: 16 February 2027
Etelcalcetide for treating secondary hyperparathyroidism (TA448)
Evidence-based recommendations on etelcalcetide (Parsabiv) for treating secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis.
Awaiting development Reference number: GID-QS10106 Expected publication date: TBC
Awaiting development Reference number: GID-QS10099 Expected publication date: TBC
Awaiting development Reference number: GID-QS10107 Expected publication date: TBC
Early value assessment (EVA) guidance on artificial intelligence (AI) technologies to aid contouring for radiotherapy treatment planning in people having external beam radiotherapy.
L-Dex U400 for lymphoedema after breast cancer treatment (MIB111)
NICE has developed a medtech innovation briefing (MIB) on L-Dex U400 for lymphoedema after breast cancer treatment .
In development Reference number: GID-QS10188 Expected publication date: TBC
In development Reference number: GID-TA11613 Expected publication date: TBC
In development Reference number: GID-TA11230 Expected publication date: 07 May 2026